Profil

Reenaers Catherine

Département des sciences de la santé publique

See author's contact details
Main Referenced Co-authors
Louis, Edouard  (86)
Van Kemseke, Catherine  (34)
Belaiche, Jacques  (30)
Vieujean, Sophie  (28)
Seidel, Laurence  (15)
Main Referenced Keywords
Humans (21); Crohn's disease (19); Female (11); Inflammatory bowel disease (10); Adult (9);
Main Referenced Unit & Research Centers
GETAID (1)
Laboratoire de gastro-entérologie translationnelle (1)
Main Referenced Disciplines
Gastroenterology & hepatology (91)
General & internal medicine (7)
Immunology & infectious disease (4)
Surgery (3)
Hematology (2)

Publications (total 105)

The most downloaded
1139 downloads
REENAERS, C., Mary, J.-Y., Nachury, M., Bouhnik, Y., Laharie, D., Allez, M., Fumery, M., Amiot, A., Savoye, G., Altwegg, R., Devos, M., Malamut, G., Bourreille, A., Flourie, B., Marteau, P., Vuitton, L., Coffin, B., Viennot, S., Lambert, J., ... Louis, E. (2018). Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2017.09.061 https://hdl.handle.net/2268/217809

The most cited

256 citations (Scopus®)

Louis, E., Michel, V., Hugot, J. P., Reenaers, C., Fontaine, F., Delforge, M., El Yafi, F., Colombel, J. F., & Belaiche, J. (April 2003). Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut, 52 (4), 552-557. doi:10.1136/gut.52.4.552 https://hdl.handle.net/2268/23738

Pierre, N., Huynh-Thu, V. A., Baiwir, D., VIEUJEAN, S., Bequet, E., Reenaers, C., Van Kemseke, C., Salée, C., Massot, C., Fleron, M., Mazzucchelli, G., Trzpiot, L., Eppe, G., De Pauw, E., Louis, E., & Meuwis, M.-A. (02 February 2024). Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease [Poster presentation]. Belgian Week of Gastroenterology 2024, Antwerp, Belgium.
Peer reviewed

MONIN, L., Reenaers, C., Grandfils, S., Latour, P., Van Kemseke, C., KROPP, S., Louis, E., & VIEUJEAN, S. (2024). Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study [Poster presentation]. Belgian Week of Gastroenterology 2024.
Peer reviewed

Pierre, N., Huynh-Thu, V. A., Baiwir, D., VIEUJEAN, S., Bequet, E., Reenaers, C., Van Kemseke, C., Salée, C., Massot, C., Fleron, M., Mazzucchelli, G., Trzpiot, L., Eppe, G., De Pauw, E., Louis, E., & Meuwis, M.-A. (2024). Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease [Poster presentation]. European Crohn's and Colitis Organisation 2024, Stockholm, Sweden.
Peer reviewed

Pierre, N., Huynh-Thu, V. A., Baiwir, D., VIEUJEAN, S., Bequet, E., Reenaers, C., Van Kemseke, C., Salée, C., Massot, C., Fleron, M., Mazzucchelli, G., Trzpiot, L., Eppe, G., De Pauw, E., Louis, E., & Meuwis, M.-A. (2024). Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease [Paper presentation]. Belgian Week of Gastroenterology 2024.
Peer reviewed

Uzzan, M., Nachury, M., Nuzzo, A., Amiot, A., Caron, B., Benezech, A., Buisson, A., Bouguen, G., Le Berre, C., Reenaers, C., Le Cosquer, G., Savoye, G., Charkaoui, M., Vidon, M., Guillo, L., Fumery, M., Peyrin-Biroulet, L., Kirchgesner, J., Bouhnik, Y., & GETAID TOFA-PRO study, G. (2024). Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjad169
Peer Reviewed verified by ORBi

Stepniak, M., Adam, P., Salée, C., Loly, J.-P., VIEUJEAN, S., Reenaers, C., Fonzé, F., Massot, C., COIMBRA MARQUES, C., DECKER, E., BLETARD, N., Delvenne, P., Speca, S., Louis, E., & Meuwis, M.-A. (2024). Study of the role of the epithelium in the initiation and progression of intestinal fibrosis in Ulcerative Colitis [Paper presentation]. Belgian Week of Gastroenterology 2024.
Peer reviewed

Adam, P., Salée, C., Stepniak, M., Loly, J.-P., VIEUJEAN, S., KROPP, S., Reenaers, C., Fonzé, F., Massot, C., BLETARD, N., COIMBRA MARQUES, C., DECKER, E., Delvenne, P., Louis, E., & Meuwis, M.-A. (2024). Characterization of the impact of NKCC1 in colorectal carcinogenesis [Paper presentation]. Belgian Week of Gastroenterology 2024.
Peer reviewed

MONIN, L., Reenaers, C., Grandfils, S., Latour, P., Van Kemseke, C., KROPP, S., Louis, E., & VIEUJEAN, S. (2024). Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study [Poster presentation]. European Crohn's and Colitis Organisation 2024.
Peer reviewed

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (11 September 2023). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. HIV Cure Symposium 2023, Gand, Belgium.

Bacha, R. A., Bouhnik, Y., Serrero, M., Filippi, J., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWit, O., Vuitton, L., Mathieu, N., Peyrin-Biroulet, L., Gilletta, C., ... Picon, L. (Other coll.). (2023). Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID. Digestive and Liver Disease. doi:10.1016/j.dld.2023.05.008
Peer reviewed

Loly, J.-P., Vieujean, S., Reenaers, C., Van Kemseke, C., Seidel, L., Louis, E., & Somja, J. (2023). In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab. Inflammatory Bowel Diseases. doi:10.1093/ibd/izad066
Peer Reviewed verified by ORBi

Vieujean, S., GILLARD, R., Calvaer, F., Chayeb, M., Seidel, L., Reenaers, C., KROPP, S., Van Kemseke, C., Latour, P., Louis, E., & Meunier, P. (March 2023). Assessment of therapeutic response in Crohn’s disease by dynamic contrast enhanced MRI [Poster presentation]. 35th Belgian Week of Gastroenterology 2023.
Peer reviewed

Peyrin-Biroulet, L., Rahier, J.-F., Kirchgesner, J., Abitbol, V., Shaji, S., Armuzzi, A., Karmiris, K., Gisbert, J. P., Bossuyt, P., Helwig, U., Burisch, J., Yanai, H., Doherty, G. A., Magro, F., Molnar, T., Löwenberg, M., Halfvarson, J., Zagorowicz, E., Rousseau, H., ... Coutard, L. (Other coll.). (March 2023). I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 21 (3), 771-788.e10. doi:10.1016/j.cgh.2022.09.018
Peer Reviewed verified by ORBi

Gofflot, A., MONIN, L., Seidel, L., Reenaers, C., KROPP, S., Van Kemseke, C., Latour, P., Forthomme, B., Croisier, J.-L., Louis, E., & Vieujean, S. (March 2023). Impact of different types of physical activity in inflammatory bowel disease [Paper presentation]. 35th Belgian Week of Gastroenterology 2023.
Peer reviewed

Vieujean, S., GILLARD, R., Calvaer, F., Chayeb, M., Seidel, L., Reenaers, C., KROPP, S., Van Kemseke, C., Latour, P., Louis, E., & Meunier, P. (March 2023). Assessment of therapeutic response in Crohn’s disease by dynamic contrast enhanced MRI [Poster presentation]. 35th Belgian Week of Gastroenterology 2023.
Peer reviewed

Amiot, A., Bourrier, A., Gornet, J.-M., Dewit, O., Nancey, S., Altwegg, R., Abitbol, V., Laharie, D., Reenaers, C., Gagnière, C., Buisson, A., Nachury, M., Viennot, S., Vuitton, L., Stefanescu, C., Marteau, P., Bouguen, G., Seksik, P., & GETAID-INFOPRO study, G. (March 2023). Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study. Infection Prevention in Practice, 5 (1), 100267. doi:10.1016/j.infpip.2022.100267
Peer Reviewed verified by ORBi

Gofflot, A., MONIN, L., Seidel, L., Reenaers, C., KROPP, S., Van Kemseke, C., Latour, P., Forthomme, B., Croisier, J.-L., Louis, E., & Vieujean, S. (March 2023). Impact of different types of physical activity in inflammatory bowel disease [Poster presentation]. 18th Congress of European Crohn's and Colitis Organisation 2023.
Peer reviewed

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (21 February 2023). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. Conference on Retroviruses and Opportunistic Infection (CROI 2023), Seattle, United States.

Vieujean, S., Moens, A., Hassid, D., Rothfuss, K., Savarino, E., Vavricka, S. R., Reenaers, C., Jacobsen, B., Allez, M., Ferrante, M., Rahier, J. F., & ECCO CONFER investigators. (2023). Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease - A case series. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjac153
Peer Reviewed verified by ORBi

Reenaers, C., GILLARD, R., Coimbra, C., GILLARD, R., Meunier, P., LECHANTEUR, C., BAUDOUX, E., BOUTAFFALA, L., Beguin, Y., & Louis, E. (2023). Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s disease: results from a prospective monocentric study. Journal of Crohn's and Colitis, 17, 728-737. doi:10.1093/ecco-jcc/jjac192
Peer Reviewed verified by ORBi

Fombellida-Lopez, C., Pasternak, A. O., Cicilionyté, A., Maes, N., Vanwinge, C., Ormenese, S., Ladang, A., Cavalier, E., Winchester, L., Fletcher, C., SUSIN, F., VAIRA, D., Hayette, M.-P., Reenaers, C., Moutschen, M., & Darcis, G. (23 November 2022). Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults [Poster presentation]. Belgium Research on AIDS and HIV Consortium (BREACH 2022), Bruxelles, Belgium.

Guillo, L., Amiot, A., Serrero, M., Altwegg, R., Roblin, X., Atanasiu, C., Buisson, A., Le Berre, C., Reenaers, C., Gornet, J.-M., Laharie, D., Abitbol, V., Biron, A., Caron, B., Nancey, S., Chupin, A., Blain, A., Vuitton, L., Caillo, L., ... Bonnet-Dodel, M. (Other coll.). (September 2022). Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. Digestive Diseases and Sciences, 67 (9), 4525-4532. doi:10.1007/s10620-022-07445-4
Peer Reviewed verified by ORBi

Amiot, A., Laharie, D., Malamut, G., Serrero, M., Poullenot, F., educational committee of the, G. E. T. A. I. D., Peyrin-Biroulet, L. (Other coll.), Laharie, D. (Other coll.), Bourreille, A. (Other coll.), Vuitton, L. (Other coll.), Bouguen, G. (Other coll.), Abitbol, V. (Other coll.), Amiot, A. (Other coll.), Biron, A. (Other coll.), Bourrier, A. (Other coll.), Caillo, L. (Other coll.), Fumery, M. (Other coll.), Gilletta, C. (Other coll.), Plastaras, L. (Other coll.), ... Wils, P. (Other coll.). (September 2022). Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. Digestive and Liver Disease, 54 (9), 1162-1167. doi:10.1016/j.dld.2022.06.020

Cottron, C., Treton, X., Altwegg, R., Reenaers, C., Amiot, A., Fumery, M., Vuitton, L., Peyrin-Biroulet, L., Bouguen, G., Dewit, O., Nancey, S., Caillo, L., Roblin, X., Beylot-Barry, M., Rivière, P., & Laharie, D. (30 August 2022). How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. Journal of Crohn's and Colitis, 16 (8), 1202-1210. doi:10.1093/ecco-jcc/jjac035
Peer Reviewed verified by ORBi

Reenaers, C., & Louis, E. (May 2022). Nouveautés dans la prise en charge des maladies inflammatoires chroniques intestinales. Revue Médicale de Liège, 77 (5-6), 323-329.
Editorial Reviewed verified by ORBi

Reenaers, C., Vieujean, S., COIMBRA MARQUES, C., GILLARD, R., Meunier, P., BOUTAFFALA, L., & Louis, E. (March 2022). Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn's disease: results from a prospective monocentric study [Paper presentation]. 34th Belgian Week of Gastroenterology 2022.
Peer reviewed

Loly, J.-P., Vieujean, S., Reenaers, C., Van Kemseke, C., Seidel, L., Somja, J., & Louis, E. (March 2022). Remission state in inflammatory bowel disease patients on anti-TNF or vedolizumab: a confocal endomicroscopy study [Paper presentation]. 34th Belgian Week of Gastroenterology 2022.
Peer reviewed

Reenaers, C., Vieujean, S., COIMBRA MARQUES, C., BOUTAFFALA, L., GILLARD, R., Meunier, P., & Louis, E. (March 2022). Efficacité et sécurité du traitement par cellules souches mésenchymateuses hématopoïétiques dans les lésions ano-périnéales de maladie de Crohn : résultats d’une étude prospective monocentrique [Paper presentation]. Journées Francophones D’hépato-Gastroenterologie Et D’oncologie Digestive.
Peer reviewed

MOREAU, A.-C., SEIDEL, L., VIEUJEAN, S., REENAERS, C., & LOUIS, E. (January 2022). Impact clinique de la vidéocapsule endoscopique du grêle dans les saignements digestifs inexpliqués. Etude rétrospective monocentrique. Revue Médicale de Liège, 77 (1), 25-31.
Editorial Reviewed verified by ORBi

Reenaers, C., & Louis, E. (2022). Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn's Disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjab166
Peer reviewed

AMICONE, C., Marques, C. C., Reenaers, C., Van Kemseke, C., Seidel, L., & Louis, E. (2022). Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn's Disease: A Retrospective Study of Three Successive Cohorts. Gastroenterology Research and Practice, 2022, 6341069. doi:10.1155/2022/6341069
Peer Reviewed verified by ORBi

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154
Peer Reviewed verified by ORBi

LOLY, J.-P., VIEUJEAN, S., REENAERS, C., VAN KEMSEKE, C., SEIDEL, L., SOMJA, J., & LOUIS, E. (01 January 2022). P234 Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study. Journal of Crohn's and Colitis, 16 (Supplement_1), 283-i283. doi:10.1093/ecco-jcc/jjab232.361
Peer Reviewed verified by ORBi

Reenaers, C., De Roover, A., KOHNEN, L., Nachury, M., Simon, M., Pourcher, G., Trang-Poisson, C., Rajca, S., Msika, S., Viennot, S., Alttwegg, R., Serrero, M., Seksik, P., Peyrin-Biroulet, L., Picon, L., Bourbao Tournois, C., Gontier, R., Gilletta, C., Stefanescu, C., ... Coffin, B. (2022). Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID. Inflammatory Bowel Diseases. doi:10.1093/ibd/izab249
Peer Reviewed verified by ORBi

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (October 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. United European Gastroenterology.
Peer reviewed

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., Pariente, B., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & LOUIS, E. (July 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study [Poster presentation]. 16th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2021 Virtual.
Peer reviewed

Pouillon, L., Remen, T., AMICONE, C., Louis, E., Maes, S., REENAERS, C., Germain, A., Baumann, C., Bossuyt, P., & Peyrin-Biroulet, L. (2021). Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.05.027
Peer Reviewed verified by ORBi

Nachury, M., Bouhnik, Y., Serrero, M., Filippi, J., Roblin, X., Kirchgesner, J., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWit, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., Gilletta, C., ... Reenaers, C. (Other coll.). (2021). Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Digestive and Liver Disease. doi:10.1016/j.dld.2020.10.020
Peer Reviewed verified by ORBi

Monin, L., Dubois, S., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., VAN DAELE, D., VIEUJEAN, S., SEIDEL, L., & Louis, E. (2021). Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort. Digestive and Liver Disease. doi:10.1016/j.dld.2020.10.040
Peer reviewed

Lambin, T., Amiot, A., Stefanescu, C., Gornet, J.-M., Seksik, P., Laharie, D., Reenaers, C., Bourreille, A., Cadiot, G., Carbonnel, F., Dib, N., Fumery, M., Gilletta de St Joseph, C., Filippi, J., Viennot, S., Plastaras, L., Coffin, B., Serrero, M., Nahon, S., ... UGT-CD-stricture GETAID study, G. (November 2020). Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Digestive and Liver Disease, 52 (11), 1323-1330. doi:10.1016/j.dld.2020.08.034

Preda, C., Manuc, T., Chifulescu, A. E., Istratescu, D., Louis, E., Baicus, C., Sandra, I., Diculescu, M., Reenaers, C., VAN KEMSEKE, C., Nitescu, M., Tieranu, C., Popescu, M. C., Tugui, L., Andrei, A., Ciora, C.-A., Gheorghe, L.-S., & Manuc, M. (2020). Diet as an environmental trigger in inflammatory bowel disease: A retrospective comparative study in two European cohorts. Revista Espanola de Enfermedades Digestivas, 112 (6), 440-447. doi:10.17235/reed.2020.6552/2019

Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Trang-Poisson, C., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., ... Amiot, A. (27 September 2019). Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. Journal of Crohn's and Colitis, 13 (10), 1239-1247. doi:10.1093/ecco-jcc/jjz088
Peer Reviewed verified by ORBi

VIEUJEAN, S., MOENS, A., ROTHFUSS, K., SAVARINO, E., VAVRICKA, S., REENAERS, C., FERRANTE, M., & RAHIER, J.-F. (February 2019). Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s) [Poster presentation]. 14th Congress of ECCO.
Peer reviewed

VIEUJEAN, S., MOENS, A., ROTHFUSS, K., SAVARINO, E., VAVRICKA, S., REENAERS, C., FERRANTE, M., & RAHIER, J.-F. (February 2019). Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulators [Poster presentation]. Belgian Week of Gastroenterology - 31th edition.
Peer reviewed

Preda, C. M., Manuc, T., Istratescu, D., Louis, E., Baicus, C., Sandra, I., Diculescu, M., REENAERS, C., VAN KEMSEKE, C., Nitescu, M., Tieranu, C., Sandu, C. G., Oprea-Calin, G., Tugui, L., Viziru, S., Ciora, C.-A., Gheorghe, L.-S., & Manuc, M. (2019). Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel Disease - a Retrospective Comparative Study. Mædica, 14 (3), 233-239. doi:10.26574/maedica.2019.14.3.233

Pierre, N., Salee, C., MASSOT, C., BLETARD, N., Mazzucchelli, G., Smargiasso, N., Morsa, D., Baiwir, D., De Pauw, E., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Delvenne, P., Meuwis, M.-A., & Louis, E. (2019). Proteomics highlights common and distinct pathophysiological processes associated with ileal and colonic ulcers in Crohn's disease. Journal of Crohn's & colitis. doi:10.1093/ecco-jcc/jjz130
Peer reviewed

Reenaers, C., Bossuyt, P., Hindryckx, P., Vanpoucke, H., Cremer, A., & Baert, F. (October 2018). Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterology Journal, 6 (8), 1117-1125. doi:10.1177/2050640618784046
Peer Reviewed verified by ORBi

Pierre, N., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Mazzucchelli, G., Smargiasso, N., Baiwir, D., Morsa, D., De Pauw, E., MEUWIS, M.-A., & Louis, E. (2018). Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn’s ulcers. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjx180.184
Peer Reviewed verified by ORBi

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time [Poster presentation]. 30th edition of Belgian Week of Gastroenterology.
Peer reviewed

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Étude dans la vie réelle de l’association d’un traitement immunosuppresseur avec l’Infliximab et l’Adalimumab dans la colite ulcéreuse [Poster presentation]. Journées Francophones d'Hépato-gastroentérologie et d'Oncologie Digestive.

Pierre, N., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Mazzucchelli, G., Smargiasso, N., Baiwir, D., De Pauw, E., MEUWIS, M.-A., & LOUIS, E. (February 2018). Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn’s ulcers [Poster presentation]. 30th edition of the Belgian Week of Gastroenterology, Anvers, Belgium.

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time in ulcerative colitis [Poster presentation]. 13th Congress of ECCO, Vienna, Austria.
Peer reviewed

REENAERS, C., Mary, J.-Y., Nachury, M., Bouhnik, Y., Laharie, D., Allez, M., Fumery, M., Amiot, A., Savoye, G., Altwegg, R., Devos, M., Malamut, G., Bourreille, A., Flourie, B., Marteau, P., Vuitton, L., Coffin, B., Viennot, S., Lambert, J., ... Louis, E. (2018). Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2017.09.061
Peer Reviewed verified by ORBi

Lorenzo, D., Maire, F., Stefanescu, C., Gornet, J.-M., Seksik, P., Serrero, M., Bournet, B., Marteau, P., Amiot, A., Laharie, D., Trang, C., Coffin, B., Bellaiche, G., Cadiot, G., Reenaers, C., Racine, A., Viennot, S., Pauwels, A., Bouguen, G., ... Viennot, S. (Other coll.). (January 2018). Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 16 (1), 59-67. doi:10.1016/j.cgh.2017.07.033
Peer Reviewed verified by ORBi

De Vos, M., Dhooghe, B., Vermeire, S., Louis, E., Mana, F., Elewaut, A., Bossuyt, P., Baert, F., REENAERS, C., Van Gossum, M., Macken, E., Ferrante, M., Hindryckx, P., Dewit, O., Holvoet, T., & Franchimont, D. (2018). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal, 6 (3), 439-445. doi:10.1177/2050640617722310
Peer Reviewed verified by ORBi

Van de Vondel, S., Baert, F., Vanden Branden, S., Amininejad, L., Dewint, P., Van Moerkercke, W., Rahier, J.-F., Hindryckx, P., Bossuyt, P., Ferrante, M., Reenaers, C., & Louis, E. (Other coll.). (2018). Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Inflammatory Bowel Diseases, 24 (5), 1099-1105. doi:10.1093/ibd/izx103
Peer Reviewed verified by ORBi

Bossuyt, P., Baert, F., D'Heygere, F., Nakad, A., REENAERS, C., Fontaine, F., Franchimont, D., Dewit, O., Van Hootegem, P., Vanden Branden, S., Lambrecht, G., Ferrante, M., & Louis, E. (Other coll.). (2018). Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases. doi:10.1093/ibd/izy219
Peer Reviewed verified by ORBi

Gagnière, C., Bourrier, A., Seksik, P., Gornet, J.-M., DeWit, O., Nancey, S., Altwegg, R., Abitbol, V., Laharie, D., REENAERS, C., Buisson, A., Pariente, B., Viennot, S., Vuitton, L., Stefanescu, C., Marteau, P., Bouguen, G., Cosnes, J., Amiot, A., ... Louis, E. (Other coll.). (2018). Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 48 (7), 713-722. doi:10.1111/apt.14926

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (October 2017). Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time in ulcerative colitis [Poster presentation]. 25th UEG week, Barcelona, Spain.
Peer reviewed

Bello, C., Roseth, A., Guardiola, J., REENAERS, C., Ruiz-Cerulla, A., VAN KEMSEKE, C., Arajol, C., Reinhard, C., SEIDEL, L., & Louis, E. (2017). Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease, 49 (9), 991-996. doi:10.1016/j.dld.2017.05.009
Peer Reviewed verified by ORBi

Louis, E., VAN KEMSEKE, C., & REENAERS, C. (2017). Objective assessment of clinical disease activity. In D. C. Baumgart (Ed.), Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach (pp. 259-266). Springer, Cham - D.C. Baumgart (ed.). doi:10.1007/978-3-319-33703-6_23

DESIR, C., COIMBRA MARQUES, C., Decker, M., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., Louis, E., & Meunier, P. (2017). Comment j'explore ... la maladie de Crohn par imagerie. Revue Médicale de Liège, 72 (1), 51-56.
Peer reviewed

LOLY, J.-P., SOMJA, J., REENAERS, C., VAN KEMSEKE, C., GAST, P., & Louis, E. (2017). Endomicroscopie confocale dans la prise en charge des maladies inflammatoires chroniques de l'intestin. Revue Médicale Suisse, 13 (571), 1431-1434.
Peer Reviewed verified by ORBi

REENAERS, C., Pirard, C., VAN KEMSEKE, C., LATOUR, P., Belaiche, J., & Louis, E. (2016). Long-term evolution and predictive factors of mild inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 51 (6), 712-9. doi:10.3109/00365521.2015.1128965
Peer Reviewed verified by ORBi

Peyrin-Biroulet, L., Salleron, J., Filippi, J., REENAERS, C., Antunes, O., Filipe, V., Louis, E., Hebuterne, X., & Roblin, X. (2016). Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Journal of Crohn's and Colitis, 10 (5), 516-24. doi:10.1093/ecco-jcc/jjw008
Peer Reviewed verified by ORBi

Louis, E., Dotan, I., Ghosh, S., Mlynarsky, L., REENAERS, C., & Schreiber, S. (2015). Optimising the Inflammatory Bowel Disease Unit to Improve Quality Of Care: Expert Recommandations. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjv085

Louis, E., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., BELAICHE, J., MEUNIER, P., & COIMBRA MARQUES, C. (2015). De l'"Evidence-based Medecine" à la médecine personnalisée dans la maladie de Crohn. Revue Médicale de Liège, 70 (5-6), 316-320.

REENAERS, C., & Louis, E. (2015). Complications de la rectocolite hémorragique et impact des traitements actuels sur l'histoire naturelle de ces complications. Hépato-Gastro, 22, 38-44. doi:10.1684/hpg.2015.1190

MEUNIER, P., COUSIN, F., VAN KEMSEKE, C., REENAERS, C., LATOUR, P., BELAICHE, J., SEIDEL, L., & LOUIS, E. (2015). Persisting signs of disease activity at magnetic resonance enterocolonography predict clinical relapse and disease progression in quiescent Crohn's disease. Acta Gastro-Enterologica Belgica, 73 (3), 274-81.
Peer Reviewed verified by ORBi

Van Kemseke, C., Louis, E., & REENAERS, C. (2015). LE MEDICAMENT DU MOIS. Vedolizumab (Entyvio(R)), nouveau traitement des maladies inflammatoires intestinales. Revue Médicale de Liège, 70 (11), 575-82.
Peer reviewed

Poncin, M., REENAERS, C., VAN KEMSEKE, C., Belaiche, J., Seidel, L., MEUNIER, P., & Louis, E. (2014). Depth of remission in Crohn's disease patients seen in a referral centre : associated factors and impact on disease outcome. Acta Gastro-Enterologica Belgica, 77 (1), 41-6.
Peer Reviewed verified by ORBi

Benitez, J.-M., Meuwis, M.-A., REENAERS, C., VAN KEMSEKE, C., Meunier, P., & Louis, E. (2013). Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut, 62 (12), 1806-16. doi:10.1136/gutjnl-2012-303957
Peer Reviewed verified by ORBi

Baert, F., Glorieus, E., REENAERS, C., D'Haens, G., Peeters, H., Franchimont, D., Dewit, O., Caenepeel, P., LOUIS, E., & Van Assche, G. (2013). Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. Journal of Crohn's and Colitis, 7 (2). doi:10.1016/j.crohns.2012.03.018
Peer Reviewed verified by ORBi

REENAERS, C., Louis, E., Belaiche, J., Seidel, L., Keshav, S., & Travis, S. (2013). Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply. Alimentary Pharmacology and Therapeutics, 37 (7), 752-3. doi:10.1111/apt.12245
Peer Reviewed verified by ORBi

Louis, E., REENAERS, C., Meuwis, M.-A., VAN KEMSEKE, C., LATOUR, P., CHAPELIER, N., WERTZ, S., COIMBRA MARQUES, C., MEUNIER, P., & Belaiche, J. (March 2012). Quinze ans d'anti-TNF dans la maladie de Crohn: comment tirer le meilleur de cette revolution therapeutique? Revue Médicale de Liège, 67 Spec No, 8-13.
Peer reviewed

Louis, E., GAST, P., VAN KEMSEKE, C., & REENAERS, C. (2012). Commentary: endoscopic dilatation for stricturing Crohn's disease. Alimentary Pharmacology and Therapeutics, 36 (5), 494-6. doi:10.1111/j.1365-2036.2012.05209.x
Peer Reviewed verified by ORBi

REENAERS, C., Belaiche, J., & Louis, E. (2012). Impact of medical therapies on inflammatory bowel disease complication rate. World Journal of Gastroenterology, 18 (29), 3823-7. doi:10.3748/wjg.v18.i29.3823
Peer Reviewed verified by ORBi

REENAERS, C., LOUIS, E., Belaiche, J., Seidel, L., Keshav, S., & Travis, S. (2012). Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Alimentary Pharmacology and Therapeutics, 36 (11-12), 1040-8. doi:10.1111/apt.12076
Peer Reviewed verified by ORBi

Louis, E., VAN KEMSEKE, C., LATOUR, P., Belaiche, J., & REENAERS, C. (2012). Genetique et environnement dans les maladies inflammatoires chroniques de l'intestin. Revue Médicale de Liège, 67 (5-6), 298-304.
Peer reviewed

VALDES SOCIN, H. G., TOME, M., LUTTERI, L., Reenaers, C., POLUS, M., Geenen, V., LOUIS, E., & Beckers, A. (2012). Auto-immune gastritis characteristics in a large series of patients with auto-immune thyroiditis. In XXIVth Belgian Week of Gastroenterology 2012 - Abstract book.

Kopylov, U., Mantzaris, G. J., Katsanos, K. H., Reenaers, C., Ellul, P., Rahier, J.-F., Israeli, E., Lakatos, P. L., Fiorino, G., Cesarini, M., Tsianos, E. V., Louis, E., & Ben-Horin, S. (2011). The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Alimentary Pharmacology and Therapeutics, 33 (3), 349-57. doi:10.1111/j.1365-2036.2010.04523.x
Peer Reviewed verified by ORBi

Louis, E., VAN KEMSEKE, C., & Reenaers, C. (2011). Necessity of phenotypic classification of inflammatory bowel disease. Best Practice and Research. Clinical Gastroenterology, 25 Suppl 1, 2-7. doi:10.1016/S1521-6918(11)70003-8
Peer Reviewed verified by ORBi

Bello, C., Belaiche, J., Louis, E., & Reenaers, C. (2011). Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Journal of Crohn's and Colitis, 5 (3), 196-202. doi:10.1016/j.crohns.2010.12.011
Peer Reviewed verified by ORBi

Momozawa, Y., Mni, M., Nakamura, K., Coppieters, W., Almer, S., Amininejad, L., Cleynen, I., Colombel, J.-F., de Rijk, P., Dewit, O., Finkel, Y., Gassull, M. A., Goossens, D., Laukens, D., Lemann, M., LIBIOULLE, C., O'Morain, C., Reenaers, C., Rutgeerts, P., ... Georges, M. (2011). Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nature Genetics, 43 (1), 43-7. doi:10.1038/ng.733
Peer Reviewed verified by ORBi

Reenaers, C., Belaiche, J., & Louis, E. (2010). Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflammatory Bowel Diseases, 16 (8), 1271-2. doi:10.1002/ibd.21162
Peer Reviewed verified by ORBi

Louis, E., Belaiche, J., & Reenaers, C. (2010). Do clinical factors help to predict disease course in inflammatory bowel disease? World Journal of Gastroenterology, 16 (21), 2600-3. doi:10.3748/wjg.v16.i21.2600
Peer Reviewed verified by ORBi

Louis, E., Libioulle, C., Reenaers, C., Belaiche, J., & Georges, M. (October 2009). Génomique des maladies inflammatoires intestinales. Revue Médicale de Liège, 64, 24-28.
Peer reviewed

Reenaers, C., Louis, E., & Belaiche, J. (2009). Thérapies biologiques et maladies inflammatoires chroniques intestinales. Revue Médicale de Liège, 64 (5-6), 301-304.
Peer reviewed

Louis, E., Belaiche, J., & Reenaers, C. (2009). Anti-tumor Necrosis Factor Nonresponders in Crohn's Disease : Therapeutic Strategies. Digestive Diseases, 27, 351-357. doi:10.1159/000228573
Peer Reviewed verified by ORBi

Louis, E., Libioulle, C., Reenaers, C., Belaiche, J., & Georges, M. (2009). Genetics of ulcerative colitis: the come-back of interleukin 10. Gut, 58 (9), 1173-6. doi:10.1136/gut.2008.169235
Peer Reviewed verified by ORBi

Louis, E., Belaiche, J., & Reenaers, C. (2009). Anti-TNF and Crohn's Disease: When Should We Stop? Current Drug Targets, 11 (2), 148-51. doi:10.2174/138945010790309957
Peer Reviewed verified by ORBi

Louis, E., Belaiche, J., & Reenaers, C. (2009). Tailoring the treatment to the individual in Crohn's disease. Therapeutic Advances in Gastroenterology, 2, 239-244. doi:10.1177/1756283X09337180
Peer Reviewed verified by ORBi

Reenaers, C., Franchimont, N., Oury, C., Belaiche, J., Malaise, M., Bours, V., Theatre, E., Delvenne, P., & Louis, E. (2008). Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. Scandinavian Journal of Gastroenterology, 43, 1334-1345. doi:10.1080/00365520802200010
Peer Reviewed verified by ORBi

Louis, E., Reenaers, C., & Belaiche, J. (2008). Are we giving biologics too much time? When should we stop treatment? World Journal of Gastroenterology, 14, 5528-5531. doi:10.3748/wjg.14.5528
Peer Reviewed verified by ORBi

Louis, E., Reenaers, C., & Belaiche, J. (2008). Does the behavior of Crohn's disease change over time? Inflammatory Bowel Diseases, 14, 54-55. doi:10.1002/ibd.20561
Peer Reviewed verified by ORBi

Louis, E., Reenaers, C., & Belaiche, J. (2008). Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease? Inflammatory Bowel Diseases, 14, 59-60. doi:10.1002/ibd.20559
Peer Reviewed verified by ORBi

Denis, M.-A., Reenaers, C., Fontaine, F., Belaiche, J., & Louis, E. (September 2007). Assessment of endoscopic activity lndex and biological lnflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflammatory Bowel Diseases, 13 (9), 1100-1105. doi:10.1002/ibd.20178
Peer Reviewed verified by ORBi

Delwaide, J., Reenaers, C., Gerard, C., Vaira, D., Bastens, B., Serwir, B., Bekhti, A., Bataille, C., Wain, E., De Leeuw, P., Daenen, G., Mesureur, T., Sente, J. M., & Belaiche, J. (July 2006). HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin. European Journal of Gastroenterology and Hepatology, 18 (7), 707-712. doi:10.1097/01.meg.0000219103.40435.8d
Peer Reviewed verified by ORBi

Delwaide, J., Gerard, C., Reenaers, C., Vaira, D., Bastens, B., Bataille, C., Serwir, B., Maes, B., Belaiche, J., & Groupe Liegeois d'études des Virus Hepatotropes. (December 2005). Hepatitis C virus genotype 5 in southern Belgium: Epidemiological characteristics and response to therapy. Digestive Diseases and Sciences, 50 (12), 2348-2351. doi:10.1007/s10620-005-3060-4
Peer Reviewed verified by ORBi

Franchimont, N., Reenaers, C., & Louis, E. (01 April 2005). Infliximab and the bone in Crohn's disease. Alimentary Pharmacology and Therapeutics, 21 (7), 918-919. doi:10.1111/j.1365-2036.2005.02434.x
Peer Reviewed verified by ORBi

Laurent, S., Reenaers, C., Detroz, B., Detry, O., Delvenne, P., Belaiche, J., & Meurisse, M. (2005). A patient who survived total colonic ulcerative colitis surinfected by cytomegalovirus complicated by toxic megacolon and disseminated intravascular coagulation. Acta Gastro-Enterologica Belgica, 68 (2, Apr-Jun), 276-279.
Peer Reviewed verified by ORBi

Franchimont, N., Reenaers, C., Lambert, C., Belaiche, J., Bours, V., Malaise, M., Delvenne, P., & Louis, E. (December 2004). Increased expression of receptor activator of NF-kappa B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clinical and Experimental Immunology, 138 (3), 491-498. doi:10.1111/j.1365-2249.2004.02643.x
Peer Reviewed verified by ORBi

REENAERS, C., DELWAIDE, J., GERARD, C., Bastens, B., Servais, B., Bekhti, A., Wain, E., DAENEN, G., Delforge, M., MESUREUR, T., Sente, B., Belaiche, J., DE ROOVER, A., DETRY, O., HONORE, P., MEURISSE, M., Rentier, B., & VAIRA, D. (2004). HCV genotype 4 in Belgium: epidemiological characteristics. Acta Gastro-Enterologica Belgica, (67), 03.
Peer Reviewed verified by ORBi

REENAERS, C., DELWAIDE, J., GERARD, C., Bastens, B., Bataille, C., BOEMER, F., Servais, B., BELAICHE, J., DE ROOVER, A., DETRY, O., HONORE, P., Meurisse, M., Rentier, B., & VAIRA, D. (2004). HCV genotype 5: an easy to treat population. Acta Gastro-Enterologica Belgica, 67, 15.
Peer Reviewed verified by ORBi

Louis, E., Michel, V., Hugot, J. P., Reenaers, C., Fontaine, F., Delforge, M., El Yafi, F., Colombel, J. F., & Belaiche, J. (April 2003). Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut, 52 (4), 552-557. doi:10.1136/gut.52.4.552
Peer Reviewed verified by ORBi

Contact ORBi